JDRF and Arecor team to develop ultraconcentrated insulin

The JDRF, a global research foundation focused on Type 1 diabetes, and Arecor said they are partnering to advance preclinical trials of the U.K.-based formulation company’s ultraconcentrated insulin.

The two said in a press release that the goal of the partnership is to accelerate the development of a stable, rapid-acting, ultraconcentrated insulin of up to 1,000 U/mL. That dosage would not only offer a much better mealtime insulin product for people requiring more than 200 U/day, but also help toward the development of the miniaturization of delivery devices, including next-generation artificial pancreas systems for people with Type 1 diabetes.  

Under terms of the agreement, JDRF will provide up to $900,000 in milestone funding over the next year for product development to the end of preclinical pharmacokinetic/pharmacodynamic modeling. 

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

“This partnership will accelerate the development of Arecor's reformulated, ultra-concentrated, rapid-acting insulin program, which is a critical unmet need in the drive towards new miniaturized insulin-delivery technology,” Sarah Howell, CEO of Arecor, said in a statement. “Ultra-concentrated insulin is an important product component in our portfolio of next-generation diabetes products.”

Device technology like wearable continuous-administration patch pumps and implants are seen as critical new developments for people with diabetes that could improve glycemic control and compliance, thereby reducing problems like hypoglycemia and diabetic ketoacidosis.

Last month, Tandem Diabetes Care and TypeZero Technologies announced they entered into an agreement to bring together TypeZero’s artificial pancreas (AP) tech and Tandem’s t:slim Insulin Pump. A research version of the pump will be used with TypeZero’s AP tech in the International Diabetes Closed Loop Trial, which takes place later this year. That trial is funded by the National Institutes of Health.

- check out the release

Related Articles:
TypeZero, Tandem partner to create artificial pancreas tech 
San Diego company testing artificial pancreas made from stem cells 
Study shows artificial pancreas improves treatment for Type 1 diabetes


Suggested Articles

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

ApiJect systems snared a $590 million from the U.S. government to build a multi-facility campus to crank out more than 3 billion injectors per year.

A team at the University of New South Wales Sydney developed a light-activated liposome that could deliver CRISPR treatments with fewer side effects.